
|Articles|September 25, 2014
- Gynecologic Cancers (Issue 1)
- Volume 1
- Issue 1
Trabectedin as a Treatment Option for Patients with Ovarian Cancer
Author(s)Bradley Monk, MD
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Advertisement
Bradley Monk, MD, gynecologic oncologist, University of Arizona Cancer Center Phoenix Branch, discusses trabectedin as a potential agent to treat ovarian cancer.
Read about research into ovarian cancer > >
Articles in this issue
over 11 years ago
The Role of Molecular Testing in Gynecologic Cancersover 11 years ago
Dream Team Aims To Change the Face of Ovarian Cancer Researchover 11 years ago
On The Horizon for Ovarian Cancer: Potentially Promising TreatmentsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















